Skip to main content
OpenTrials
Completed

NCT Number: NCT05066685

Characteristics of Patients With Neovascular Age-related Macular Degeneration Enrolled in the Brolucizumab Patient Support Services Program

The study was a retrospective, cross-sectional, descriptive study of patients with wet AMD who enrolled in the brolucizumab Patient Support Services (PSS) program. Evidence was generated to describe their baseline demographic and clinical characteristics.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Age-related Macular Degeneration (AMD) Eye Diseases Macular Degeneration Retinal Degeneration Retinal Diseases

Age range

19 year–65 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Novartis Investigative Site

East Hanover, New Jersey, 07936-1080, United States

About this study

The study was a retrospective, cross-sectional, descriptive study of patients with wet AMD who enrolled in the brolucizumab Patient Support Services (PSS) program.

PSS data was obtained from patients with wet AMD who enrolled in the program for the index period 10/10/2019 to 04/30/2020.

  • Identification period of the index period: 10/10/2019 to 04/30/2020
  • Index date: Date of enrollment in the PSS program
  • Study Period: 10/10/2019 to 04/30/2020

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients were enrolled in the brolucizumab PSS program
  • ≥19 years old

Exclusion criteria

  • None

Treatment and study plan

All Participants

Other

All the particpants enrolled in the brolucizumab Patient Support Services (PSS) program

Primary outcomes

  1. Number of patients with Primary plan type

    Time frame: Index date defined as the date of enrollment in the PSS program

    The primary plan type for patients with wet AMD enrolled in the brolucizumab patient support services program were reported. The primary Plan type include commercial, government or other insurance.

Secondary outcomes

  1. Age

    Time frame: Index date defined as the date of enrollment in the PSS program

    Age information of patients enrolled in the brolucizumab PSS program was reported

  2. Gender

    Time frame: Index date defined as the date of enrollment in the PSS program

    Gender information of patients enrolled in the brolucizumab PSS program was reported

  3. Patient region (by state)

    Time frame: Index date defined as the date of enrollment in the PSS program

    Distribution of patients across US states

  4. Provider region (by state)

    Time frame: Index date defined as the date of enrollment in the PSS program

    Number of providers and their distribution across US states

  5. Insurance coverage

    Time frame: Index date defined as the date of enrollment in the PSS program

    The insurance coverage details for all the patients with wet AMD was reported

  6. Number of patients with Secondary plan type

    Time frame: Index date defined as the date of enrollment in the PSS program

    The secondary plan type for patients with wet AMD enrolled in the brolucizumab patient support services program were reported. The secondary plan included commercial, government or other insurance

  7. Disease Status

    Time frame: Index date defined as the date of enrollment in the PSS program

    The eye disease status of all the patients were reported. Disease status was categorized as Right eye, left eye, or bilateral

Sponsors and collaborators

Lead sponsor

Novartis Pharmaceuticals

Industry

Registry information

Important dates

Study start
2020
Primary completion
2020
Study completion
2020
First posted
Oct 4, 2021
Registry last updated
Oct 12, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.